Onepot AI just dropped a 13M seed round that reads like a who’s who of people who only show up when the future is already sneaking in through the side door. Fifty Years led, with Khosla Ventures, Speedinvest, Script Capital, NAVEC Investment Management, Wojciech Zaremba and Jeff Dean locking in behind them. When that roster signs the check, the message is simple. The chemistry world is about to get pulled into the fast lane whether it’s ready or not. Major congrats to Onepot AI and to CEO and Co-founder Daniil Boiko and Co-founder Andrei Tyrin, who decided that waiting months for a single molecule was a tax on progress the industry never should have tolerated in the first place.
The magic trick here is that Onepot AI did not go chasing the shiny part of the drug discovery hype cycle. They went straight for the part everyone complained about but nobody wanted to rebuild. POT-1, their automated synthesis lab in SF, operates as a self-driving kitchen for small molecules, with an AI chemist named Phil calling the plays. Phil is not a mascot and not a lab toy. Phil plans reactions, runs hardware, reads LC/MS outputs, learns from every hit and every miss and does it all in real time. That is why POT-1 can take turnaround times that used to drag for months and compress them to about 5 days. It is not whirlwind disruption. It is industrial discipline running at AI speed.
And then there is the catalog. 1.9M compounds available for on-demand synthesis. Pick what you need, click it, and Onepot AI builds it in a fully automated lab that logs every detail down to reagent quirks. For biotech teams drowning in bottlenecks, that is not convenience. That is oxygen. With a 2nd, larger facility about to break ground in SF, the signal is unmistakable. This is not a pilot. This is scale.
There is a deeper business play here that founders should study like scripture. Investors back people who attack the friction, not the fantasy. Daniil Boiko and Andrei Tyrin did not promise a prettier molecular model. They built the infrastructure that makes the molecules show up on time. They solved the part of the DMTA cycle that quietly bankrupts momentum. You want a lesson in why funding flows? There it is. Fix the slowdown nobody else wants to touch, and capital becomes a magnet.
For pharma, biotech and materials teams stuck waiting on CRO timelines that feel like watching paint dry in slow motion, Onepot AI is the partner that turns the waiting room into a runway. Faster builds, US-based automation, reproducibility that survives turnover and a platform already proving it can outpace human chemists by 6 to 10 times. The early partners know exactly what that means, and the growing waitlist shows the rest of the market can smell the shift coming.
Startups Startup Funding Venture Capital Seed Round AI Automation Biotech Healthcare HealthTech Deep Tech Infrastructure Technology Innovation Tech Ecosystem Startup Ecosystem
